6:11 PM
 | 
Mar 29, 2007
 |  BC Extra  |  Top Story

Provenge's pregnant pause

Traders anticipate a dramatic run-up in shares of Dendreon (DNDN) on Friday after an FDA advisory panel voted 13-4 late Thursday that the company had provided substantial evidence of the efficacy of Provenge sipuleucel-T to treat asymptomatic patients with metastatic, androgen-independent prostate cancer. Provenge is the first cancer vaccine to go before the FDA.

DNDN didn't trade during the day on Thursday or in...

Read the full 314 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >